Form 8-K - Current report:
SEC Accession No. 0000950170-24-135212
Filing Date
2024-12-11
Accepted
2024-12-11 07:45:09
Documents
13
Period of Report
2024-12-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prld-20241211.htm   iXBRL 8-K 48945
2 EX-99.1 prld-ex99_1.htm EX-99.1 35775
3 GRAPHIC img268059179_0.jpg GRAPHIC 5700
  Complete submission text file 0000950170-24-135212.txt   245640

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20241211.xsd EX-101.SCH 50257
15 EXTRACTED XBRL INSTANCE DOCUMENT prld-20241211_htm.xml XML 4721
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 241540152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)